Ultime notizie per AstraZeneca (NASDAQ:AZN) Azioni

AstraZeneca

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.

Possible Reversal

News

Markets

AMGN

Nuovi dazi in arrivo? Il mercato azionario reagisce con cali significativi sui principali produttori di farmaci.

Trump fa crollare anche i titoli farmaceutici: ecco cosa ha detto stavolta

Il colosso farmaceutico lancia la sfida ai farmaci più gettonati contro l&#39;obesità con un nuovo trattamento: ecco cosa rivelano gli studi.

È questo il miglior prodotto per perdere peso? Amgen sfida Ozempic e Zepbound

Specialty ETFs

ETFs

DBEF

NOVO

Crescita inattesa nel vecchio continente: quali strumenti finanziari offrono la migliore esposizione al mercato e minimizzano i rischi?

I grandi fondi puntano sull&#39;Europa, devi farlo anche tu? 3 ETF da tenere d&#39;occhio

AstraZeneca PLC - American Depositary Shares

AstraZeneca PLC

Precidian ETFs Trust AstraZeneca PLC ADRhedged

AZN Capital Corp

<a href="https://www.youtube.com/watch?v=z-16fImZoEc">https://www.youtube.com/watch?v=z-16fImZoEc</a>
&nbsp;

Biotech

General

BNTX

MRNA

NVAX

U.S. CDC Advisory Panel Votes 5-1 In Favor Of Children 18 Years & Younger Receiving Seasonal Flu Vaccine Only In Single Dose Forms That Are Free From Thimerosal; Of Pregnant Women Receiving Seasonal Flu Vaccine Only In Single Dose Forms That Are Free From Thimerosal; Of All Adults Receiving Seasonal Flu Shot Only In Single Dose Forms That Are Free From Thimerosal

U.S. CDC Vaccine Advisory Panel Votes 7-0 In Favor Of Adding Preventive RSV Therapies To Vaccines For Children Resolution

Based on TROPION-Lung05 results and supported by data from TROPION-Lung01
First and only TROP2-directed therapy approved in the US for the treatment of lung cancer
DATROWAY&#xAE; (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy.
This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
The approval follows <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.astrazeneca-us.com%2Fmedia%2Fpress-releases%2F2025%2Fdatopotamab-deruxtecan-granted-priority-review-in-the-us-for-patients-with-previously-treated-advanced-egfr-mutated-non-small-cell-lung-cancer.html&amp;esheet=54281360&amp;newsitemid=20250624872660&amp;lan=en-US&amp;anchor=Priority+Review&amp;index=1&amp;md5=3c87087dc3b4dcb05731b7b3767293b8">Priority Review</a> and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.astrazeneca-us.com%2Fmedia%2Fpress-releases%2F2024%2Fdatopotamab-deruxtecan-granted-breakthrough-therapy-designation-in-US-for-patients-with-previously-treated-advanced-EGFR-mutated-non-small-cell-lung-cancer.html&amp;esheet=54281360&amp;newsitemid=20250624872660&amp;lan=en-US&amp;anchor=Breakthrough+Therapy+Designation&amp;index=2&amp;md5=3fa508b0d2af29da1f707270d6b398ec">Breakthrough Therapy Designation</a> by the Food and Drug Administration (FDA) based on results from a subgroup analysis of the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04484142&amp;esheet=54281360&amp;newsitemid=20250624872660&amp;lan=en-US&amp;anchor=TROPION-Lung05&amp;index=3&amp;md5=4a4583d901ffdf4601f3e067fd76ea6d">TROPION-Lung05</a> Phase II trial and supported by data from the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04656652&amp;esheet=54281360&amp;newsitemid=20250624872660&amp;lan=en-US&amp;anchor=TROPION-Lung01&amp;index=4&amp;md5=1b64c4b4b6ef0812fb4ab4b39de5cc13">TROPION-Lung01</a> Phase III trial.
In TROPION-Lung05 and TROPION-Lung01, DATROWAY demonstrated a confirmed ORR of 45% (95% confidence interval [CI]: 35-54) in patients with previously treated locally advanced or metastatic EGFR-mutated NSCLC (n=114) as assessed by blinded independent central review (BICR). Complete responses were seen in 4.4% of patients and partial responses were seen in 40% of patients. The median DoR was 6.5 months (95% CI: 4.2-8.4).
The safety profile of DATROWAY was evaluated in a pooled analysis of 125 patients in the TROPION-Lung05, TROPION-Lung01 and TROPION-PanTumor01 trials. The safety profile observed across these trials was consistent with the known profile of this medicine with no new safety concerns identified.
DATROWAY is a specifically engineered TROP2-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.
AstraZeneca and Daiichi Sankyo are evaluating DATROWAY alone and with TAGRISSO (osimertinib) in other advanced or metastatic EGFR-mutated NSCLC settings in the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06350097&amp;esheet=54281360&amp;newsitemid=20250624872660&amp;lan=en-US&amp;anchor=TROPION-Lung14&amp;index=5&amp;md5=fc2790367273e630655d1329bd920135">TROPION-Lung14</a> and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06417814&amp;esheet=54281360&amp;newsitemid=20250624872660&amp;lan=en-US&amp;anchor=TROPION-Lung15&amp;index=6&amp;md5=e031955113b4cfe3867f8fbd2917e03b">TROPION-Lung15</a> Phase III trials.
Financial considerations Following approval in the US, an amount of $45 million is due from AstraZeneca to Daiichi Sankyo as a milestone payment for the locally advanced or metastatic EGFR-mutated NSCLC indication. Sales of DATROWAY in the US are recognized by Daiichi Sankyo.

AstraZeneca Says DATROWAY Approved In US For Treatment Of Adult Patients With Locally Advanced Or Metastatic EGFR-Mutated NSCLC Who Have Received Prior EGFR-Directed Therapy And Platinum-Based Chemotherapy

The Food and Drug Administration (FDA) on Monday approved AstraZeneca Plc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) Datroway (datopotamab deruxtecan or Dato-DXd) for adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-Directed therapy and <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">platinum-based chemotherapy</a>.
Following the U.S. approval, $45 million is due from AstraZeneca to Daiichi Sankyo Co., Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DSKYF#OTC">DSKYF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DSNKY#OTC">DSNKY</a>) as a milestone payment for the locally advanced or metastatic EGFR-mutated NSCLC indication. Daiichi Sankyo recognizes Datroway&#8217;s sales in the U.S.
This indication is <a target="_blank" href="https://www.astrazeneca.com/media-centre/press-releases/2025/datroway-approved-in-us-for-egfrm-lung-cancer.html" rel="noreferrer noopener">approved</a> under accelerated approval based on objective response rate (ORR) and duration of response (DoR).
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/06/45924585/astrazeneca-inks-research-pact-with-chinas-cspc-pharmaceuticals-focused-on-ai-driven-research-valued-up-to-5-33-billion" rel="noreferrer noopener">AstraZeneca Inks Research Pact With China&#8217;s CSPC Pharmaceuticals Focused On AI-Driven Research, Valued Up To $5.33 Billion</a>
Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
The approval is based on results from a subgroup analysis of the TROPION-Lung05 Phase 2 trial and supported by data from the TROPION-Lung01 Phase 3 trial.
In TROPION-Lung05 and TROPION-Lung01, Datroway demonstrated a confirmed ORR of 45% in patients with previously treated locally advanced or metastatic EGFR-mutated NSCLC (n=114).
Complete responses were seen in 4.4% of patients, and partial responses were seen in 40%. The median DoR was 6.5 months.
Datroway is a specifically engineered TROP2-directed DXd antibody-drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.
Dave Fredrickson, Executive Vice President, Oncology Haematology Business Unit, AstraZeneca, said: &#8220;This first approval of Datroway in lung cancer provides a much-needed option to patients with advanced EGFR-mutated lung cancer whose disease has become resistant to past treatments, regardless of the driving mutation.&#8221;
AstraZeneca and Daiichi Sankyo are evaluating Datroway alone and with Tagrisso (osimertinib) in other advanced or metastatic&nbsp;EGFR-mutated NSCLC settings in the <a target="_blank" href="https://clinicaltrials.gov/study/NCT06350097" rel="noreferrer noopener">TROPION-Lung14</a> and <a target="_blank" href="https://clinicaltrials.gov/study/NCT06417814" rel="noreferrer noopener">TROPION-Lung15</a> Phase III trials.
AstraZeneca released results from three Phase 3 cancer clinical trials at the 2025 American Society of Clinical Oncology <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45729253/astrazeneca-highlights-significant-gains-across-three-major-cancer-trials-at-asco" rel="noreferrer noopener">Annual Meeting in June</a>.
Enhertu combo showed a median PFS of 40.7 months vs 26.9 months with THP in HER2+ metastatic breast cancer.
Camizestrant combo reduced disease progression risk by 56%, with a median PFS of 16.0 months vs. 9.2 months for standard care.
Price Action: AZN stock is trading higher by 0.88% to $71.26 premarket at the last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/02/43830315/bristol-myers-lead-cancer-drug-opdivo-in-combination-with-chemo-shows-improved-overall-survival-in-certain-patients-with-lung-cancer" target="_blank" rel="noreferrer noopener">Bristol Myers Cancer Drug Opdivo In Combination With Chemo Shows Improved Overall Survival In Certain Patients With Lung Cancer</a></li>
</ul>
Photo by Tada Images via Shutterstock

Large Cap

Health Care

DSKYF

DSNKY

FDA Approves AstraZeneca And Daiichi Sankyo's Datroway For EGFR-Mutated Lung Cancer

DATROWAY Approved In The U.S. As First TROP2 Directed Therapy For Patients With Previously Treated Advanced EGFR-mutated Non-Small Cell Lung Cancer; DATROWAY Is Being Jointly Developed And Commercialized By Daiichi Sankyo And AstraZeneca

AstraZeneca's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NYSE">AZN</a>) short percent of float has fallen 8.33% since its last report. The company recently reported that it has 6.92 million shares sold short, which is 0.22% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.56 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>AstraZeneca Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750435230_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for AstraZeneca has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing AstraZeneca's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, AstraZeneca's peer group average for short interest as a percentage of float is 3.86%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Is the Market Bullish or Bearish on AstraZeneca?

<a href="https://www.bloomberg.com/news/articles/2025-06-18/rfk-jr-weighs-review-of-dozens-of-shots-citing-aluminum-use" title="https://www.bloomberg.com/news/articles/2025-06-18/rfk-jr-weighs-review-of-dozens-of-shots-citing-aluminum-use">https://www.bloomberg.com/news/articles/2025-06-18/rfk-jr-weighs-review-of-dozens-of-shots-citing-aluminum-use</a>

'RFK Jr. Weighs Review of Dozens of Shots, Citing Aluminum Use' - Bloomberg News

On Friday, AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) entered a strategic research collaboration with Shijiazhuang City-based CSPC Pharmaceuticals Group Limited.
Per the agreement, AstraZeneca and CSPC <a target="_blank" href="https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-enters-into-collaboration-with-cspc.html" rel="noreferrer noopener">agree</a> to discover and develop preclinical candidates for multiple targets with the potential to treat diseases across chronic indications, including a preclinical small molecule oral therapy <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">for immunological diseases</a>.
Financial Considerations
CSPC will receive an upfront payment of $110 million and is also eligible to receive up to $1.62 billion in potential development milestone payments and up to $3.6 billion in sales milestone payments, plus potential single-digit royalties based on annual net sales of the products.
Under the agreement, AstraZeneca will have the right to exercise options for exclusive licenses to develop and commercialize worldwide candidates identified under this agreement.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45729253/astrazeneca-highlights-significant-gains-across-three-major-cancer-trials-at-asco" rel="noreferrer noopener">AstraZeneca Highlights Significant Gains Across Three Major Cancer Trials At ASCO</a>
CSPC will conduct research in Shijiazhuang City, utilizing its AI-driven, dual-engine efficient drug discovery platform.
This platform uses AI technology to analyze the binding patterns of target proteins with existing compound molecules and conduct targeted optimization to select highly effective small molecules with excellent developability.
The collaboration furthers AstraZeneca&#8217;s presence in China following the&nbsp;$2.5 billion investment in Beijing&nbsp;announced earlier this year and strengthens the ongoing collaboration with CSPC.
In March, the European pharma giant said the investment over the next five years is part of a strategic partnership with the Beijing Municipal Government and the Beijing Economic-Technological Development Area Administrative Office, which includes agreements with three biotechs and follows the <a target="_blank" href="https://www.benzinga.com/25/02/43859578/amid-mounting-pressure-in-china-astrazeneca-buys-fibrogens-chinese-unit-for-160-million-and-gains-access-to-anemia-drug" rel="noreferrer noopener">recent Fibrogen announcement</a>.
AstraZeneca expects its Beijing workforce to grow to 1,700 employees.
In October 2024, AstraZeneca entered into an exclusive license agreement with CSPC Pharmaceutical to advance the development of an early-stage, novel small molecule Lipoprotein (a) (Lp(a)) disruptor for dyslipidemia, a condition characterized by abnormal levels of lipids (fats) in the blood.&nbsp;
It&#8217;s a significant risk factor for cardiovascular disease, including heart attack and stroke.
Under the agreement, AstraZeneca <a target="_blank" href="https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-licenses-lipid-lowering-lpa-asset.html" rel="noreferrer noopener">received</a> access to CSPC&#8217;s preclinical candidate small molecule, YS2302018, as a lipid-lowering therapy with potential in a range of cardiovascular disease indications alone or in combination, including with the oral small molecule PCSK9 inhibitor AZD0780.
CSPC received an upfront payment of $100 million from AstraZeneca and is also eligible to receive up to $1.92 billion for further development and commercialization milestones, plus tiered royalties.
Price Action: At the last check on Friday, AZN stock was down 0.53% to $74.60 during the premarket session.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/m-a/25/06/45907865/biontech-mrna-cancer-portfolio-curevac-all-stock-deal" target="_blank" rel="noreferrer noopener">BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal</a></li>
</ul>
Photo: Shutterstock

Contracts

AstraZeneca Inks Research Pact With China's CSPC Pharmaceuticals Focused On AI-Driven Research, Valued Up To $5.33 Billion

AstraZeneca Has Entered A Strategic Research Collaboration With Shijiazhuang City-based CSPC Pharmaceuticals For Oral Candidates To Treat Diseases Across Multiple Indications, CSPC Will Receive An Upfront Payment Of $110M, And Is Also Eligible To Receive Up To $1.62B In Potential Development Milestone Payments And Up To $3.6B In Sales Milestone Payments, Plus Potential Single-digit Sales Based Royalties.

Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) on Thursday released results from APPULSE-PNH, a Phase 3B study evaluating the efficacy and safety of twice-daily oral monotherapy Fabhalta (iptacopan) in adult patients with <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">paroxysmal nocturnal hemoglobinuria (PNH)</a> with Hb levels ≥10g/dL who switched from anti-C5 therapies (eculizumab or ravulizumab).
The company released topline <a target="_blank" href="https://www.benzinga.com/24/12/42370119/novartis-touts-encouraging-data-from-late-stage-study-for-fabhalta-in-rare-type-of-blood-disorder" rel="noreferrer noopener">data in December 2024</a>.
What Happened: PNH is a rare complement-mediated blood disorder. People with PNH have an acquired mutation in some of their hematopoietic stem cells that causes them to produce RBCs susceptible to premature destruction.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/45075714/novartis-q1-earnings-beat-street-view-ceo-confident-to-deliver-upgraded-2025-guidance" rel="noreferrer noopener">Novartis Q1 Earnings Beat Street View, CEO &#8216;Confident&#8217; In Delivering Upgraded Guidance</a>
This leads to intravascular hemolysis (destruction of RBCs within blood vessels) and extravascular hemolysis (destruction of RBCs mostly in the spleen and liver).
After 24 <a target="_blank" href="https://www.novartis.com/news/media-releases/novartis-fabhalta-shows-statistically-significant-and-clinically-meaningful-improvements-hemoglobin-new-population-patients-pnh" rel="noreferrer noopener">weeks</a> of treatment with Fabhalta, the Hb level improved&nbsp;on average by 2.01 g/dL, with most patients achieving normal or near-normal levels.
Data will be presented at the European Hematology Association (EHA) Congress 2025.
No patients required transfusion during the study, and the vast majority (92.7%) achieved Hb ≥12g/dL, reaching normal or near-normal levels. Patients treated with Fabhalta also reported clinically meaningful improvements in fatigue (as measured by FACIT-Fatigue score) through Day 168, reaching absolute levels similar to those reported in the general population.
Furthermore, patients treated with Fabhalta maintained intravascular hemolysis control and resolved extravascular hemolysis control, as demonstrated by lactate dehydrogenase levels (&lt;1.5 upper limit of normal) and a reduction in absolute reticulocyte count.
Alongside APPULSE-PNH, longer-term data from patients initially included in the APPLY-PNH and APPOINT-PNH Phase 3 studies will be presented at EHA.
Why It Matters: Novartis says Anti-C5 therapies, including AstraZeneca Plc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) Soliris (eculizumab) or Ultomiris (ravulizumab), are commonly administered every two to eight weeks as intravenous infusions, and treatment visits (including journey, waiting, infusion and recovery time) can take approximately four to five hours.
Despite treatment with anti-C5 therapies, a large proportion of people with PNH remain anemic, and some are dependent on blood transfusions.
NVS Price Action: NVS stock is up 2.17% at $120.54 at publication on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/biotech/25/01/42978906/regeneron-pipeline-aims-to-address-220-billion-therapeutic-opportunities-by-2030" target="_blank" rel="noreferrer noopener">Regeneron Pipeline Aims To Address $220 Billion Therapeutic Opportunities By 2030</a></li>
</ul>
Photo: Shutterstock

Movers

Novartis' Fabhalta Delivers Hemoglobin Gains, Reduces Fatigue In Patients With Rare Blood Disorder

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$320.00</td>
<td>$46.9K</td>
<td>13.5K</td>
<td>12.3K</td>
</tr>
<tr>
<td>BSX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$100.00</td>
<td>$1.3 million</td>
<td>580</td>
<td>1.5K</td>
</tr>
<tr>
<td>HIMS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$52.00</td>
<td>$54.2K</td>
<td>3.1K</td>
<td>998</td>
</tr>
<tr>
<td>VERA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$22.50</td>
<td>$108.7K</td>
<td>5.4K</td>
<td>781</td>
</tr>
<tr>
<td>REPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$12.50</td>
<td>$28.3K</td>
<td>23</td>
<td>437</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$80.00</td>
<td>$38.8K</td>
<td>3.5K</td>
<td>300</td>
</tr>
<tr>
<td>TEM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$60.00</td>
<td>$114.0K</td>
<td>314</td>
<td>214</td>
</tr>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$75.00</td>
<td>$94.2K</td>
<td>2.3K</td>
<td>153</td>
</tr>
<tr>
<td>AZN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$72.50</td>
<td>$33.4K</td>
<td>855</td>
<td>143</td>
</tr>
<tr>
<td>DOCS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$67.50</td>
<td>$27.8K</td>
<td>155</td>
<td>110</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a call option sweep with bullish sentiment. It expires in 8 day(s) on June 20, 2025. Parties traded 102 contract(s) at a $320.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $46.9K, with a price of $460.0 per contract. There were 13587 open contracts at this strike prior to today, and today 12314 contract(s) were bought and sold. 
• For BSX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>), we notice a put option trade that happens to be bullish, expiring in 371 day(s) on June 18, 2026. This event was a transfer of 1500 contract(s) at a $100.00 strike. The total cost received by the writing party (or parties) was $1.3 million, with a price of $920.0 per contract. There were 580 open contracts at this strike prior to today, and today 1500 contract(s) were bought and sold. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a put option sweep with bearish sentiment. It expires in 8 day(s) on June 20, 2025. Parties traded 525 contract(s) at a $52.00 strike. This particular put needed to be split into 54 different trades to become filled. The total cost received by the writing party (or parties) was $54.2K, with a price of $104.0 per contract. There were 3124 open contracts at this strike prior to today, and today 998 contract(s) were bought and sold. 
• For VERA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>), we notice a call option trade that happens to be bearish, expiring in 36 day(s) on July 18, 2025. This event was a transfer of 750 contract(s) at a $22.50 strike. The total cost received by the writing party (or parties) was $108.7K, with a price of $145.0 per contract. There were 5422 open contracts at this strike prior to today, and today 781 contract(s) were bought and sold. 
• For REPL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>), we notice a call option sweep that happens to be bullish, expiring in 36 day(s) on July 18, 2025. This event was a transfer of 334 contract(s) at a $12.50 strike. This particular call needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $28.3K, with a price of $85.0 per contract. There were 23 open contracts at this strike prior to today, and today 437 contract(s) were bought and sold. 
• Regarding NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we observe a call option trade with bullish sentiment. It expires in 582 day(s) on January 15, 2027. Parties traded 20 contract(s) at a $80.00 strike. The total cost received by the writing party (or parties) was $38.8K, with a price of $1940.0 per contract. There were 3586 open contracts at this strike prior to today, and today 300 contract(s) were bought and sold. 
• For TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we notice a put option sweep that happens to be bearish, expiring in 64 day(s) on August 15, 2025. This event was a transfer of 200 contract(s) at a $60.00 strike. This particular put needed to be split into 18 different trades to become filled. The total cost received by the writing party (or parties) was $114.0K, with a price of $570.0 per contract. There were 314 open contracts at this strike prior to today, and today 214 contract(s) were bought and sold. 
• For MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we notice a put option sweep that happens to be bearish, expiring in 281 day(s) on March 20, 2026. This event was a transfer of 152 contract(s) at a $75.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $94.2K, with a price of $620.0 per contract. There were 2354 open contracts at this strike prior to today, and today 153 contract(s) were bought and sold. 
• For AZN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), we notice a put option trade that happens to be bearish, expiring in 99 day(s) on September 19, 2025. This event was a transfer of 130 contract(s) at a $72.50 strike. The total cost received by the writing party (or parties) was $33.4K, with a price of $257.0 per contract. There were 855 open contracts at this strike prior to today, and today 143 contract(s) were bought and sold. 
• Regarding DOCS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>), we observe a call option trade with bullish sentiment. It expires in 64 day(s) on August 15, 2025. Parties traded 100 contract(s) at a $67.50 strike. The total cost received by the writing party (or parties) was $27.8K, with a price of $278.0 per contract. There were 155 open contracts at this strike prior to today, and today 110 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

DOCS

Hims & Hers Health, Inc. Class A Common Stock

HIMS

REPL

VERA

10 Health Care Stocks With Whale Alerts In Today's Session

IonQ Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NASDAQ">IONQ</a>) is solidifying its stronghold in the quantum computing space as a recent sector endorsement by Jensen Huang, partnership with Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), and the <a href="https://www.benzinga.com/m-a/25/06/45832398/ionq-buys-oxford-ionics-in-1-075-billion-deal-to-supercharge-quantum-tech">acquisition of Oxford Ionics</a> have drawn investor attention to the company.
What Happened: Its recent definitive agreement to acquire U.K.-based Oxford Ionics for $1.075 billion will &#8220;meaningfully accelerate IonQ&#8217;s technology roadmap,&#8221; said Needham.
This strategic move propels IonQ towards ambitious targets: a 256 physical qubit system by 2026, 10,000 physical qubits by 2027, and a staggering 2 million physical qubits by 2030, all while achieving increasingly higher logical accuracy.
Needham highlights that these targets will be achieved as IonQ leverages Oxford&#8217;s ion-trap technology and uses its own control software, networking stack, and manufacturing capabilities
Needham &amp; Company has reiterated its &#8220;Buy&#8221; rating on IonQ, maintaining a $50 price target in a note dated June 11.
This comes as Nvidia CEO Huang turned back on his <a href="https://www.benzinga.com/markets/equities/25/01/42867168/nvidias-jensen-huang-said-something-that-has-all-quantum-computing-stocks-tumbling-qubt-and-rgti-down-13-ionq-down-11">January statement</a>, and said quantum computing is reaching a pivotal &#8220;<a href="https://www.benzinga.com/markets/tech/25/06/45885805/nvidias-jensen-huang-sparks-quantum-stock-frenzy">inflection point</a>,&#8221; during his keynote speech at a company event being held jointly with the VivaTech 2025 conference in Paris. 
He also added that quantum computing is poised to &#8220;solve some interesting problems&#8221; globally in the coming years.
See Also: <a href="https://www.benzinga.com/markets/macro-economic-events/25/06/45900891/mark-cuban-backs-ro-khannas-12-trillion-progressive-deficit-reduction-plan-targetin">Mark Cuban Backs Ro Khanna&#8217;s $12 Trillion &#8216;Progressive Deficit Reduction Plan,&#8217; Targeting Medicare Fraud And Military Spending</a>
Why It Matters: The path to practical quantum advantage increasingly involves hybrid quantum-classical computing, and IonQ has demonstrated its leadership in this domain after a partnership with Nvidia.
It is already working on <a href="https://ionq.com/news/ionq-to-advance-hybrid-quantum-computing-with-new-chemistry-application-and">hybrid computing</a>, leveraging the NVIDIA CUDA-Q platform alongside its IonQ Forte hardware. This collaboration illustrates the seamless integration of quantum processing units (QPUs) with Nvidia&#8217;s accelerated computing capabilities. 
Further solidifying this synergy, IonQ, in partnership with AstraZeneca PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), Amazon.com Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) Amazon Web Services (AWS), and Nvidia, recently achieved a remarkable 20 times speedup in a <a href="https://ionq.com/news/ionq-speeds-quantum-accelerated-drug-development-application-with#:~:text=COLLEGE%20PARK%2C%20MD%20%2D%20June%209,quantum%2Daccelerated%20computational%20chemistry%20workflow">critical drug development workflow</a>. 
Price Action: Shares of IonQ ended 0.10% lower on Wednesday, and they were down 1.81% in premarket on Friday. It has fallen 7.89% on a year-to-date basis and surged 399.37% over a year.
About seven analysts covering IonQ are <a href="https://www.benzinga.com/quote/IONQ/analyst-ratings">tracked by Benzinga</a>. They have a consensus target price of $40 apiece, with a ‘hold' rating. The targets range from $30 to $50, and the recent ratings by Needham, Benchmark, and Morgan Stanley imply a 10.91% upside for the stock.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/IONQ/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="384" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12075115/ANR-IONQ-1024x384.png" alt="" class="wp-image-947500" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12075115/ANR-IONQ-1024x384.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12075115/ANR-IONQ-300x113.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12075115/ANR-IONQ-768x288.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12075115/ANR-IONQ.png 1282w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Benzinga Edge Stock Rankings shows that IonQ had a stronger price trend over the short, medium, and long term. Its momentum ranking was solid; however, its value ranking was poor at the 3.20th percentile. The details of other metrics are <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">available here</a>.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="148" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12074600/IONQ-EDGE-1024x148.png" alt="" class="wp-image-947495" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12074600/IONQ-EDGE-1024x148.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12074600/IONQ-EDGE-300x43.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12074600/IONQ-EDGE-768x111.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12074600/IONQ-EDGE.png 1044w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were lower in premarket on Thursday. The SPY was down 0.51% at $598.30, while the QQQ declined 0.54% to $529.51, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/45899298/automotive-and-apparel-companies-absorbed-tariff-costs-amid-better-than-expected-may-cpi-print-but-dont-expect-that-to-continue-says-expert">Automotive And Apparel Companies &#8216;Absorbed Tariff Costs&#8217; Amid Better Than Expected May CPI Print: &#8216;But Don&#8217;t Expect That To Continue,&#8217; Says Expert</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image Via Shutterstock

AMZN

IONQ

NVDA

Jensen Huang's Quantum Support Boosts IonQ's Growth Plans: Nvidia Partnership, Oxford Ionics Deal Lead Needham To Reiterate 'Buy'

IonQ, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>)&nbsp;shares traded higher Monday after the company announced results of a collaborative research program with AstraZeneca PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), Amazon Web Services and NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) to develop and demonstrate a quantum-accelerated computational chemistry workflow.
What To Know: IonQ said the partnership delivered over a 20x speed improvement compared to previous methods used in early-stage drug development research. The project integrated IonQ's quantum computing hardware with AWS and Nvidia platforms to reduce processing time from months to days.
The company said this marks its most complex demonstration to date and highlights the potential for quantum computing to accelerate pharmaceutical research.
"This demonstration with AstraZeneca represents a meaningful step toward practical quantum computing applications," said IonQ CEO Niccolo de Masi.
IONQ Price Action: IonQ stock closed Monday 2.67% higher at $40.06, according to data from <a href="https://www.google.com/url?sa=t&amp;source=web&amp;rct=j&amp;opi=89978449&amp;url=https://www.benzinga.com/pro/&amp;ved=2ahUKEwj1irjk3-SNAxXGlIkEHS5zGGoQFnoECAsQAQ&amp;usg=AOvVaw0xIsPvjIcIIsWev01-6zR2">Benzinga Pro</a>.
See Also: • <a href="https://www.benzinga.com/trading-ideas/previews/25/06/45846835/gamestop-q1-earnings-preview-bitcoin-on-the-balance-sheet-but-dont-expect-much-detail">GameStop Q1 Earnings Preview: Bitcoin On The Balance Sheet, But Don&#8217;t Expect Much Detail</a>
Image via Shutterstock

Tech

What's Going On With IonQ Shares Monday?

French drugmaker Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) on Monday said it is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure broad availability well ahead of the 2025-2026 respiratory syncytial virus (RSV) season, which typically starts in November and <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">runs through March</a>.
Sanofi, in collaboration with its partner AstraZeneca plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), has tripled production capacity and doubled the number of manufacturing sites since the launch of Beyfortus in 2023.
Immunizations <a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2025/2025-06-09-05-00-00-3095598" rel="noreferrer noopener">begin</a> in early fall. The current supply for the upcoming season matches the total doses distributed last year, and production continues.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45726872/regeneron-experimental-weight-loss-drug-with-novo-nordisks-wegovy-helps-preserve-lean-mass-in-mid-stage-study" rel="noreferrer noopener">Regeneron&#8217;s Obesity Trial With Novo Nordisk&#8217;s Wegovy Hits Lean Target</a>
Sanofi said Beyfortus duration of protection was extended for six months in the EU. This year&#8217;s EU shipments are marked by an important change to the Beyfortus EU label, extending the duration of protection through six months so Beyfortus can continue to offer season-long protection for all infants, including older babies immunized just before the RSV season begins.
More than six million babies have been immunized worldwide, and millions more will be immunized this season in more than 40 countries to help protect them from the potentially devastating impact of RSV disease.
In another development, Regeneron Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) and Sanofi on Saturday presented results from the DISCOVER Phase 4, single-arm, open-label trial assessing Dupixent&nbsp;(dupilumab) in adults and adolescents with moderate-to-severe atopic dermatitis <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45828306/dupixent-dupilumab-data-at-revolutionizing-atopic-dermatitis-rad-conference-reinforce-use-in-atopi" rel="noreferrer noopener">with skin of color</a>.
These are the first clinical trial results for Dupixent in a large population of patients with darker skin tones.
The results, along with the Dupixent Phase 3 trials, demonstrated patients taking Dupixent experienced improvements in signs and symptoms of atopic dermatitis from baseline across many skin tones.
The data were shared at the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference. In the trial, 120 patients with atopic dermatitis and skin of color were treated with Dupixent every two weeks using a weight-based dosing regimen.
At 24 weeks:
<ul class="wp-block-list">
<li>76% achieved a ≥75% improvement in overall disease severity (EASI-75), the primary endpoint. Some patients saw improvements as early as two weeks.</li>
<li>53% achieved clinically meaningful improvement in itch (≥4-point reduction on the peak-pruritus numerical rating scale [PP-NRS]). Improvements were seen by some patients as early as two weeks.</li>
<li>Patients experienced a 53% reduction from baseline in post-inflammatory hyperpigmentation, dropping from 5.1 points (moderate/marked) to 2.4 points (mild).</li>
<li>Based on patient reporting, 18% were very or extremely bothered by dry skin, compared to 78% at baseline.</li>
<li>The safety results in the DISCOVER trial were generally consistent with the known safety profile of Dupixent in its approved dermatological indications.</li>
</ul>
Price Action: REGN stock was trading higher by 1.53% to $500.75, and SNY stock was down 0.99% at $49.97.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45817049/arcutis-unveils-long-term-efficacy-safety-for-zoryve-cream-in-pediatric-patients-with-atopic-dermatitis" target="_blank" rel="noreferrer noopener">Arcutis Unveils Long-Term Efficacy, Safety For Zoryve Cream In Pediatric Patients With Atopic Dermatitis</a></li>
</ul>
Photo by HJBC via Shutterstock

REGN

Beyfortus Output Tripled As Sanofi, AstraZeneca Scale Up For RSV Season

AstraZeneca Doses First Patient In DESTINY-Endometrial01 Phase 3 Trial Evlauating ENHERTU In Combination With Rilvegostomig Or Pembrolizumab Versus Platinum-Based Chemotherapy In Combination With Pembrolizumab As First-Line Therapy In Patients With HER2 Expressing Mismatch Repair Proficient Primary Advanced Or Recurrent Endometrial Cancer

<ul>
<li>Largest demonstration of its kind combines leading hardware, platforms, and techniques to achieve 20 times speedup over previous demonstrations</li>
<li>Ecosystem collaboration marks significant step toward designing more efficient ways of producing pharmaceuticals</li>
<li>IonQ will showcase demonstration at ISC High Performance conference in Hamburg, Germany</li>
</ul>

IonQ, AstraZeneca, AWS, And NVIDIA Demonstrate 20x Speedup In Quantum-Accelerated Drug Development Workflow

Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season

Sanofi And AstraZeneca Accelerate Global Rollout Of Beyfortus To Deliver Season-Long Respiratory Syncytial Virus Protection In Over 40 Countries

<a href="https://www.statnews.com/2025/06/05/glp-1-drugs-low-but-elevated-risk-of-age-related-macular-degeneration/?utm_campaign=rss" title="https://www.statnews.com/2025/06/05/glp-1-drugs-low-but-elevated-risk-of-age-related-macular-degeneration/?utm_campaign=rss">https://www.statnews.com/2025/06/05/glp-1-drugs-low-but-elevated-risk-of-age-related-macular-degeneration/?utm_campaign=rss</a>

'GLP-1 Drugs May Be Linked To Elevated Risk Of Serious Eye Disease, Study Finds' - STAT News

<a href="https://www.dailymail.co.uk/health/article-14773791/ozempic-weight-loss-drugs-kidney-cancer-risk-study.html" title="https://www.dailymail.co.uk/health/article-14773791/ozempic-weight-loss-drugs-kidney-cancer-risk-study.html">https://www.dailymail.co.uk/health/article-14773791/ozempic-weight-loss-drugs-kidney-cancer-risk-study.html</a>

"Exclusive: Ozempic Linked To 'Silent Cancer' That Is Rising In Young People As Doctors Issue Shock Warning" - DailyMail+

AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) on Monday released results from <a href="https://www.benzinga.com/general/health-care">three Phase 3 clinical trials</a> at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting: DESTINY-Breast09, MATTERHORN, and SERENA-6.
DESTINY-Breast09 trial
In the DESTINY-Breast09 trial, <a href="https://www.astrazeneca.com/media-centre/press-releases/2025/enhertu-plus-pertuzumab-reduced-the-risk-of-disease-progression-or-death-vs-thp-as-1st-line-therapy-in-patients-with-her2-positive-metastatic-breast-cancer.html">Enhertu</a> (trastuzumab deruxtecan) combined with pertuzumab was evaluated as a first-line treatment for HER2-positive metastatic breast cancer, compared to a standard regimen of a taxane, trastuzumab, and pertuzumab (THP).
Topline data <a href="https://www.benzinga.com/general/biotech/25/04/44894989/astrazeneca-daiichi-sankyos-multi-billion-dollar-cancer-drug-shows-superior-efficacy-across-broad" target="_blank" rel="noreferrer noopener">were shared in April</a>.
Also Read: <a href="https://www.benzinga.com/general/biotech/25/05/45168310/astrazenecas-triple-combination-therapy-breztri-hits-primary-goals-in-two-pivotal-studies-for-asthma" target="_blank" rel="noreferrer noopener">AstraZeneca&#8217;s Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma</a>
Results indicated that the Enhertu combination reduced the risk of disease progression or death by 44%. Median progression-free survival (PFS) reached 40.7 months with the Enhertu regimen versus 26.9 months for THP, a benefit observed across patient subgroups.
Investigator-assessed median PFS was 40.7 months for the Enhertu arm and 20.7 months for THP. The confirmed objective response rate was 85.1% for the Enhertu combination and 78.6% for THP, with 58 complete responses in the Enhertu group compared to 33 with THP. 
The median duration of response was 39.2 months for the Enhertu combination and 26.4 months for THP. Overall survival data was not yet mature, though an early trend favored the Enhertu combination.
MATTERHORN trial
The MATTERHORN trial assessed <a href="https://www.astrazeneca-us.com/media/press-releases/2025/IMFINZI-durvalumab-regimen-reduced-risk-of-progression-recurrence-or-death-by-29-percent-in-early-stage-gastric-cancer-vs-chemotherapy-alone-in-MATTERHORN-Phase-III-trial.html?utm_source=external-comms&amp;utm_medium=memo&amp;utm_campaign=asco2025&amp;utm_term=corporate&amp;utm_content=matterhorn">Imfinzi</a> (durvalumab) with standard FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) chemotherapy as a perioperative treatment for resectable, early-stage, and locally advanced gastric and gastroesophageal junction (GEJ) cancers, compared to chemotherapy alone.
Topline data <a href="https://www.benzinga.com/general/biotech/25/03/44188407/astrazenecas-imfinzi-based-regimen-shows-improved-event-free-survival-in-early-stage-gastric-canc" target="_blank" rel="noreferrer noopener">were released in March</a>.
A planned interim analysis showed that the Imfinzi-based regimen led to a 29% reduction in the risk of disease progression, recurrence, or death. 
Median event-free survival (EFS) was not reached in the Imfinzi arm, compared to 32.8 months in the chemotherapy-alone arm. The estimated 24-month EFS rate was 67.4% for the Imfinzi regimen and 58.5% for chemotherapy alone. 
A trend towards improved overall survival was noted for the Imfinzi-based regimen, with formal assessment to follow.
SERENA-6 trial
The SERENA-6 trial investigated <a href="https://www.astrazeneca-us.com/media/press-releases/2025/Camizestrant-reduced-the-risk-of-disease-progression-or-death-by-56-in-patients-with-advanced-HR-positive-breast-cancer-with-an-emergent-ESR1-tumor-mutation-in-SERENA-6-Phase-III-trial.html?utm_source=external-comms&amp;utm_medium=memo&amp;utm_campaign=asco2025&amp;utm_term=corporate&amp;utm_content=serena-6">camizestrant</a> combined with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) in patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer whose tumors developed an ESR1 mutation during first-line treatment with an aromatase inhibitor (AI) and a CDK4/6 inhibitor.
Topline data were <a href="https://www.benzinga.com/25/02/43975577/astrazenecas-investigational-cancer-drug-shows-first-line-benefit-in-combination-with-widely-cancer-medicines" target="_blank" rel="noreferrer noopener">shared in February</a>.
The trial compared switching to the camizestrant combination against continuing the AI plus CDK4/6 inhibitor. The camizestrant combination reduced the risk of disease progression or death by 56%. 
Median PFS was 16.0 months for patients who switched, versus 9.2 months for those continuing the AI combination. The median time to deterioration of global health status was 23.0 months for the camizestrant arm and 6.4 months for the AI combination arm. 
While data for time to second disease progression and overall survival were immature, a trend favored the camizestrant combination for PFS2.
Price Action: AZN stock is trading lower by 0.95% at $72.14 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45726872/regeneron-experimental-weight-loss-drug-with-novo-nordisks-wegovy-helps-preserve-lean-mass-in-mid-stage-study" target="_blank" rel="noreferrer noopener">Regeneron&#8217;s Obesity Trial With Novo Nordisk&#8217;s Wegovy Hits Lean Target</a></li>
</ul>
Photo by Piotr Swat Shutterstock

AstraZeneca Highlights Significant Gains Across Three Major Cancer Trials At ASCO

Press Releases

Danaher Announces Diagnostic Development and Commercialization Partnership to Scale Precision Medicine

ENHERTU® Reduced the Risk of Death by 30% Versus Ramucirumab Plus Paclitaxel as a Second-Line Therapy in Patients with HER2 Positive Unresectable or Metastatic Gastric Cancer in DESTINY-Gastric04 Phase 3 Trial

Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial

IMFINZI® (durvalumab) regimen reduced risk of progression, recurrence or death by 29% in early-stage gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial

DATROWAY® Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Cancer

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial

ENHERTU® Plus Pertuzumab Reduced the Risk of Disease Progression or Death by 44% Versus THP as First-Line Therapy in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast09 Phase 3 Trial

DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer

DATROWAY® Approved in the U.S. as First TROP2 Directed Therapy for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

DATROWAY® approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer

TYO:4568

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Verona Pharma

Viatris

Zoetis

TD Cowen

Argus Research

Goldman Sachs

BMO Capital

Morgan Stanley

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

VRTX

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-09-30 at 5.38.54 PM

Movers & Shakers

COSM

Nestle Sponsored representing Registered Shares Series B

NSRGY

VTRS

How Cosmos Health&#39;s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

Comments

AstraZeneca

Notizie

Ultime notizie per AstraZeneca (NASDAQ:AZN) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO